Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

First Posted Date
2017-07-21
Last Posted Date
2024-12-16
Lead Sponsor
University of Nebraska
Target Recruit Count
75
Registration Number
NCT03226418
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2017-07-11
Last Posted Date
2024-12-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
116
Registration Number
NCT03214562
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

First Posted Date
2017-07-02
Last Posted Date
2023-12-11
Lead Sponsor
University Hospital Muenster
Target Recruit Count
650
Registration Number
NCT03206671
Locations
🇫🇮

Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland

🇨🇭

Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland

🇨🇭

Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland

and more 89 locations

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Phase 2
Withdrawn
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Midostaurin
Drug: Cytarabine
First Posted Date
2017-07-02
Last Posted Date
2018-10-22
Lead Sponsor
University of Florida
Registration Number
NCT03207334
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

First Posted Date
2017-06-21
Last Posted Date
2023-02-14
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
62
Registration Number
NCT03194932
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

🇺🇸

Lucille Packard Children's Hospital Stanford University, Palo Alto, California, United States

🇺🇸

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

First Posted Date
2017-06-09
Last Posted Date
2019-08-20
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
48
Registration Number
NCT03181815
Locations
🇨🇳

Liang Wang, Guangzhou, Guangdong, China

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2017-05-23
Last Posted Date
2024-05-29
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
206
Registration Number
NCT03164057
Locations
🇺🇸

Rady Children's Hospital and Health Center, San Diego, California, United States

🇺🇸

Children's Hospital of Central California, Madera, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

and more 7 locations

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

First Posted Date
2017-05-12
Last Posted Date
2024-12-27
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
310
Registration Number
NCT03150693
Locations
🇺🇸

Fairbanks Memorial Hospital, Fairbanks, Alaska, United States

🇺🇸

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States

🇺🇸

Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States

and more 456 locations

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

First Posted Date
2017-05-10
Last Posted Date
2024-03-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT03147612
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

First Posted Date
2017-05-01
Last Posted Date
2020-03-06
Lead Sponsor
Gilead Sciences
Target Recruit Count
9
Registration Number
NCT03135028
Locations
🇯🇵

University of Fukui Hospital, Fukui, Japan

🇯🇵

Tokai University Hospital, Kanagawa, Japan

🇯🇵

Tohoku University Hospital, Miyagi, Japan

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy